7,022 Shares in Omnicell, Inc. (NASDAQ:OMCL) Purchased by Sei Investments Co.

Sei Investments Co. purchased a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 7,022 shares of the company’s stock, valued at approximately $313,000.

Several other institutional investors and hedge funds have also bought and sold shares of OMCL. Geode Capital Management LLC increased its stake in shares of Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock valued at $48,176,000 after buying an additional 2,877 shares during the period. Shaker Investments LLC OH bought a new stake in Omnicell in the fourth quarter valued at $550,000. Exchange Traded Concepts LLC increased its position in Omnicell by 6.7% during the 4th quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock valued at $14,232,000 after purchasing an additional 20,031 shares during the period. Empowered Funds LLC bought a new position in Omnicell in the 4th quarter worth $388,000. Finally, SG Americas Securities LLC lifted its position in shares of Omnicell by 56.5% in the 4th quarter. SG Americas Securities LLC now owns 39,359 shares of the company’s stock worth $1,752,000 after purchasing an additional 14,202 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

OMCL has been the topic of several research analyst reports. Bank of America reduced their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Monday, March 24th. Benchmark restated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. Wells Fargo & Company decreased their price objective on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, March 20th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Omnicell presently has an average rating of “Hold” and a consensus price target of $51.00.

Omnicell Stock Down 4.9 %

Shares of NASDAQ:OMCL opened at $31.08 on Friday. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 115.12, a PEG ratio of 7.53 and a beta of 0.78. The stock has a fifty day simple moving average of $36.59 and a two-hundred day simple moving average of $41.76. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.